Urtasun R C, Coleman C N, Wasserman T H, Phillips T L
Int J Radiat Oncol Biol Phys. 1984 Sep;10(9):1691-6. doi: 10.1016/0360-3016(84)90530-3.
Results of world-wide clinical trials with misonidazole are discussed. An attempt is made to assess the reasons for the lack of positive results and the cost-benefit analysis is critically reviewed. The data on the clinical investigations of the second generation misonidazole analogues SR-2508 and RO-03-8799 are presented. Emphasis is placed on future work such as tumor selection for clinical trials, reduction of drug toxicity and methods to increase the drug radiosensitizing properties. Because of the large amount of knowledge, experience, productivity and good scientific clinical data accummulated with nitroimidazoles over the past five years, it is recommended that this is the time to push forward with the work on the newest, more efficient compounds.
讨论了米索硝唑在全球范围内的临床试验结果。试图评估未取得阳性结果的原因，并对成本效益分析进行了批判性审视。介绍了第二代米索硝唑类似物SR-2508和RO-03-8799的临床研究数据。重点关注未来的工作，如临床试验的肿瘤选择、降低药物毒性以及增强药物放射增敏特性的方法。鉴于过去五年中硝基咪唑类药物积累了大量知识、经验、成果以及良好的科学临床数据，建议现在是推进最新、更高效化合物研究工作的时候了。
